In fact, a series of recent studies have importantly suggested that many targeted agents are able to achieve therapeutic concentrations in the brain, including EGFR- and ALK- inhibitors for non-small cell lung cancer, BRAF- and MEK- inhibitors for melanoma, and HER2-directed therapies for breast cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.